Provided by Tiger Trade Technology Pte. Ltd.

Q32 Bio Inc.

8.27
-1.2600-13.22%
Post-market: 8.17-0.1000-1.21%19:45 EDT
Volume:5.25M
Turnover:46.97M
Market Cap:245.69M
PE:2.76
High:10.40
Open:10.40
Low:7.88
Close:9.53
52wk High:23.57
52wk Low:1.91
Shares:29.71M
Float Shares:20.90M
Volume Ratio:6.04
T/O Rate:25.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.00
EPS(LYR):2.42
ROE:72.14%
ROA:14.74%
PB:2.32
PE(LYR):3.42

Loading ...

Analysts Offer Insights on Healthcare Companies: Q32 Bio (QTTB) and Wave Life Sciences (WVE)

TIPRANKS
·
6 hours ago

Q32 Bio Inc trading halted, volatility trading pause

TIPRANKS
·
Yesterday

NASDAQ Trade Halt Volatility Trading Pause at 09:30 Am

Reuters
·
Yesterday

Q32 Bio Reports 36-Week Phase 2a Signal-AA Data Showing 35.3% Mean SALT Score Reduction for Bempikibart in Alopecia Areata

Reuters
·
Yesterday

Q32 Bio Presents Results from Part B of the Signal-Aa Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

THOMSON REUTERS
·
Yesterday

Top Premarket Gainers

MT Newswires Live
·
Yesterday

Top Premarket Gainers

MT Newswires Live
·
Sep 29

Q32 Bio Inc. : Clear Street Initiates Coverage with Buy Rating; Price Target $38

THOMSON REUTERS
·
Sep 29

Jefferies Initiates Q32 Bio at Buy With $29 Price Target

MT Newswires Live
·
Sep 28

Q32 Bio initiated with a Buy at Jefferies

TIPRANKS
·
Sep 28

Q32 Bio to Present 36-Week Phase 2a Signal-AA Trial Data for Bempikibart in Alopecia Areata at EADV 2026

Reuters
·
Sep 22

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the Signal-Aa Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026

THOMSON REUTERS
·
Sep 21

Q32 Bio Names José Trevejo Chief Medical Officer

Reuters
·
Sep 14

Q32 Bio Appoints JosÉ Trevejo, M.d., Ph.d., as Chief Medical Officer and Ellie Hershberger, Pharm.d., as Chief Development Officer

THOMSON REUTERS
·
Sep 14

Q32 Bio on Track for Longest Losing Streak Since November 2024

Dow Jones
·
Sep 09

Q32 Bio to Present at Wells Fargo Healthcare Conference

Reuters
·
Sep 01

Q32 Bio Initiated at Overweight by Morgan Stanley

Dow Jones
·
Aug 24

Q32 Bio initiated with an Overweight at Morgan Stanley

TIPRANKS
·
Aug 24

Q32 Bio Inc. : Wells Fargo Cuts Target Price to $59 from $66

THOMSON REUTERS
·
Aug 06

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Q32 Bio (QTTB)

TIPRANKS
·
Aug 06